SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Colak, Yasar ^a   Ozturk, Oguzhan ^a   Senates, Ebubekir ^b   Tuncer, Ilyas ^a   Yorulmaz, Elif ^a   Adali, Gupse ^a   Doganay, Levent ^a   Enc, Feruze Yilmaz ^a  

^a Goztepe Government Education and Research Hospital   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Nonalcoholic fatty liver disease; Sirtuin1 (SIRT1); Treatment

Indexed keywords

RESVERATROL; SIRTUIN 1;

DEACETYLATION; DIABETES MELLITUS; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; INSULIN RELEASE; LIPID DIET; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

EID: 79955941313     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881749     Document Type: Review

References (70)

1. Ludwig J, Viggiano TR, McGill DB et al: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980; 55: 434-38
2. Bellentani S, Scaglioni F, Marino M et al: Epidemiology of non-alcoholic fatty liver disease. Dig Dis, 2010; 28: 155-61
3. Lewis JR, Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci, 2010; 55: 560-78
4. Day CP, James OF: Steatohepatitis: a tale of two "hits"? Gastroenterology, 1998; 114: 842-45
5. Jou J, Choi SS, Diehl AM: Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis, 2008; 28: 370-79
6. Torres DM, Harrison SA: Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology, 2008; 134: 1682-98
7. Huang MA, Greenson JK, Chao C et al: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol, 2005; 100: 1072-81
8. Klein S, Mittendorfer B, Eagon JC et al: Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology, 2006; 130: 1564-72
9. Ratziu V, Giral P, Jacqueminet S et al: Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology, 2008; 135: 100-10
10. Uygun A, Kadayifci A, Isik AT et al: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2004; 19: 537-44
11. Yang T, Fu M, Pestell R et al: SIRT1 and endocrine signaling. Trends Endocrinol. Metab, 2006; 17: 186-91
12. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 2006; 5: 493-506
13. Borra MT, Smith BC, Denu JM: Mechanism of human SIRT1 activation by resveratrol. J Biol Chem, 2005; 280: 17187-95
14. Howitz KT, Bitterman KJ, Cohen HY et al: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003; 425: 191-96
15. Kaeberlein M, McDonagh T, Heltweg B et al: Substrate-specific activation of sirtuins by resveratrol. J Biol Chem, 2005; 280: 17038-45
16. Cohen HY, Miller C, Bitterman KJ et al: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004; 305: 390-92
17. Milne JC, Lambert PD, Schenk S et al: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007; 450: 712-16
18. Van den Berghe G: The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J Inherit Metab Dis, 1991; 14: 407-20
19. McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis, 2004; 8: 521-33
20. Deng XQ, Chen LL, Li NX: The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int, 2007; 27: 708-15
21. Chen LL, Deng XQ, Li NX: Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats. Zhonghua Yi Xue Za Zhi, 2007; 87: 1434-37
22. Purushotham A, Schug TT, Xu Q et al: Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab, 2009; 9: 327-38
23. Herranz D, Muñoz-Martin M, Cañamero M et al: Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun, 2010; 1: 3
24. Imai S, Armstrong CM, Kaeberlein M et al: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000; 403: 795-800
25. Landry J, Sutton A, Tafrov ST et al: The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA, 2000; 97(11): 5807-11
26. Smith JS, Brachmann CB, Celic I et al: A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA, 2000; 97(12): 6658-63
27. Luo J, Nikolaev AY, Imai S et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001; 107: 137-48
28. Vaziri H, Dessain SK, Ng Eaton E et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 2001; 107: 149-59
29. Yeung F, Hoberg JE, Ramsey CS et al: Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J, 2004; 23: 2369-80
30. Brunet A, Sweeney LB, Sturgill JF et al: Stresss-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004; 303: 2011-15
31. Motta MC, Divecha N, Lemieux M et al: Mammalian SIRT1 represses forkhead transcription factors. Cell, 2004; 116: 551-63
32. Rodgers JT, Lerin C, Haas W et al: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature, 2005; 434: 113-18
33. Li X, Zhang S, Blander G et al: SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell, 2007; 28: 91-106
34. Grimaldi B, Nakahata Y, Kaluzova M et al: Chromatin remodeling, metabolism and circadian clocks: The interplay of CLOCK and SIRT1. Int J Biochem Cell Biol, 2008; 41: 81-86
35. Nakahata Y, Kaluzova M, Grimaldi B et al: The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell, 2008; 134: 329-40
36. Liu Y, Dentin R, Chen D et al: A fasting inducible switch modulates gluconeogenesis via activator/coactivator Exchange. Nature, 2008; 456: 269-73
37. Yamazaki Y, Usui I, Kanatani Y et al: Treatment with SRT1720, a SIRT1 Activator, Ameliorates Fatty Liver with Reduced Expression of Lipogenic Enzymes in MSG Mice. Am J Physiol Endocrinol Metab. 2009; Sep 1. [Epub ahead of print]
38. Costa Cdos S, Hammes TO, Rohden F et al: SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg, 2010; 20: 633-39
39. Bordone L, Motta MC, Picard F et al: Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol, 2006; 4: e31
40. Moynihan KA, Grimm AA, Plueger MM et al: Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab, 2005; 2: 105-17
41. Lee JH, Song MY, Song EK et al: Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes, 2009; 58: 344-51
42. Picard F, Kurtev M, Chung N et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-g. Nature, 2004; 429: 771-76
43. Banks AS, Kon N, Knight C et al: SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 2008; 8: 333-41
44. Qiao L, Shao J: SIRT1 regulates adiponectin gene expression through Foxo1-C/EBPalpha transcriptional complex. J Biol Chem, 2006; 281: 39915-24
45. Wang H, Qiang L, Farmer SR: Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes, Mol Cell Biol, 2008; 28: 188-200
46. Attie AD, Kastelein JP, Hayden MR: Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res, 2001; 42: 1717-26
47. Oram JF, Lawn RM: ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res, 2001; 42: 1173-79
48. Gerhart-Hines Z, Rodgers JT, Bare O et al: Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. Embo J, 2007; 26: 1913-23
49. Mootha VK, Handschin C, Arlow D et al: Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA, 2004; 101: 6570-75
50. Patti ME, Butte AJ, Crunkhorn S et al: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA, 2003; 100: 8466-71
51. Sun C, Zhang F, Ge X et al: SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab, 2007; 6: 307-19
52. Elchebly M, Payette P, Michaliszyn E et al: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 1999; 283: 1544-48
53. Targher G, Arcaro G: Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 2007; 191: 235-40
54. Ekstedt M, Franzén LE, Mathiesen UL et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006; 44: 865-73
55. Targher G, Bertolini L, Padovani R et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007; 30: 1212-18
56. Das DK, Maulik N: Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv, 2006; 6: 36-47
57. Labinskyy N, Csiszar A, Veress G et al: Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem, 2006; 13: 989-96
58. Mattagajasingh I, Kim CS, Naqvi A et al: SIRT1 promotes endotheliumdependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA, 2007; 104: 14855-60
59. Novakovic A, Bukarica LG, Kanjuh V et al: Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol, 2006; 99: 360-64
60. Stef G, Csiszar A, Lerea K et al: Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol, 2006; 48: 1-5
61. Kuningas M, Putters M, Westendorp RG et al: SIRT1 gene, agerelated diseases, and mortality: the Leiden 85-plus study. J Gerontol A Biol Sci Med Sci, 2007; 62: 960-65
62. Zhang R, Chen HZ, Liu JJ et al: SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem, 2010; 285: 7097-110
63. Leiro J, Arranz JA, Fraiz N et al: Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol, 2005; 5: 393-406
64. Yoshizaki T, Milne JC, Imamura T et al: SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol, 2009; 29: 1363-74
65. Athar M, Back JH, Kopelovich L et al: Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009; 486: 95-102
66. Boily B, He XH, Pearce B et al: SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene, 2009; 28: 2882-93
67. Kundu JK, Surh YJ: Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 2008; 269: 243-46
68. Wang RH, Zheng Y, Kim HS et al: Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell, 2008; 32: 11-20
69. Whyte L, Huang YY, Torres K et al: Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res, 2007; 67: 12007-17
70. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs, 2008; 9: 371-78